Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.

Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.

Item
http://www.wikidata.org/entity/Q48883337
Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study.Monoclonal antibodies in lung cancer.Strategies targeting angiogenesis in advanced non-small cell lung cancer.Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis.Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumFirst-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis.[Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer].Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.
P2860

Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.

Item
http://www.wikidata.org/entity/Q48883337
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Safety and efficacy of first-l ...... phase IV MO19390 (SAiL) study.
@en
Safety and efficacy of first-l ...... ults from the phase IV MO19390
@nl
type
label
Safety and efficacy of first-l ...... phase IV MO19390 (SAiL) study.
@en
Safety and efficacy of first-l ...... ults from the phase IV MO19390
@nl
prefLabel
Safety and efficacy of first-l ...... phase IV MO19390 (SAiL) study.
@en
Safety and efficacy of first-l ...... ults from the phase IV MO19390
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Safety and efficacy of first-l ...... phase IV MO19390 (SAiL) study.
@en
P2093
P304
P31
P356
10.1097/JTO.0B013E318216687D
P433
P478
P50
P577
P698
P921